
|Articles|September 1, 2002
- Volume 0 0
Insulin-Producing Stem Cells Created
Advertisement
Stem cells may hold the key to actually curing diabetes. As reported in Endocrinology (August 2002), researchers from Massachusetts General Hospital in Boston took human pancreas islet stem cells and exposed them to the hormone glucagon-like peptide-1 (GLP-1). That caused the islet stem cells to begin producing insulin. The notion is that transplanting insulin-producing cells from a person?s own stem cells will prevent rejection by the immune system. The investigators emphasize, however, that much more research is needed.
Articles in this issue
about 24 years ago
Seperate Powders??about 24 years ago
Pure testosterone isocaproate powder...about 24 years ago
Delivery of progesterone...about 24 years ago
Try a Little Exerciseabout 24 years ago
Seasonal Affective Disorderabout 24 years ago
Most Asthmatics Are Not Using Anti-inflammatory Drugsabout 24 years ago
New Guidelines on Inhaler Packaging Are Issuedabout 24 years ago
Big Babies Have Reduced Diabetes Riskabout 24 years ago
Niacin Therapyabout 24 years ago
Whole-Grain HealthAdvertisement
Related to this article

A PharmD candidate reflects on the small, evidence-backed daily habits that helped her thrive—not just survive—through pharmacy school's most demanding years.

Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.

The most enduring resources a preceptor can give students are the confidence and tools to ask deeper questions.

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.

Two recent graduates share strategies for standing out in the competitive fellowship application process.

Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5


